c-Met targeted radiotheragnostic pair (Edinburgh Molecular Imaging)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namec-Met targeted radiotheragnostic pair (Edinburgh Molecular Imaging)
Drug Alias Name[68Ga]-EMP-001 + [177Lu]-EMP-001[68Ga]-EMP-001 + [225Ac]-EMP-001EMP-001-[68Ga] + EMP-001-[177Lu]gallium-68-EMP-001 + actinium-177-EMP-001gallium-68-EMP-001 + lutetium-177-EMP-001 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptideRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) +[4] 
Mechanisms of ActionHepatocyte growth factor receptor modulatorsPositron-emission tomography enhancers
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesEdinburgh Molecular Imaging Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEdinburgh Molecular Imaging Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A